companies / mazetherapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 115,000,000115.0M | ○ |
|---|---|---|
| founded | null | |
| hq | South San Francisco CA | |
| industry | unknown | |
| stage | series-b+ |
Maze Therapeutics develops small-molecule precision medicines for renal, cardiovascular, and metabolic diseases, including obesity. It serves patients with chronic kidney disease, led by MZE829 for APOL1 kidney disease and MZE782. Its Compass platform links genetic variants to disease pathways so therapies match genetically defined patient groups.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-12-01 | series-d+ | 115,000,000115.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Series D+, $115.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |